Drugs that contain Fenfluramine Hydrochloride
1. Fintepla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947183 | UCB INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(9 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(11 years from now) | |
|
US10950331 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Mar, 2036
(11 years from now) | |
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(13 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(14 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| New Product(NP) | Jun 25, 2023 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...
Dosage: SOLUTION;ORAL
FINTEPLA family patents
